Custom Search

News

Saturday 01 February 2003

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.

By: Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, Peigue-Lafeuille H, Blanche S, Fischer A, Casanova JL, Travade P, Tardieu M.

Clin Infect Dis 2003 Feb 1;36(3):e47-9

Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.

Use of this site is subject to the following terms of use